transplant immunobiology laboratory

Research Descriptions

                          Dr. Krams' Research     

                        Dr. Martinez' Research

Recent Publications

Krams SM, Martinez OM.
Epstein-Barr virus, rapamycin, and host immune responses.
Curr Opin Organ Transplant. 2008 Dec;13(6):563-8. Review.

Vaysberg M, Hatton O, Lambert SL, Snow AL, Wong B, Krams SM, Martinez OM.
Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos.
J Biol Chem. 2008 Dec 26;283(52):36573-85. Epub 2008 Nov 5. 

Stenard F, Nguyen C, Cox K, Kambham N, Umetsu DT, Krams SM, Esquivel CO, Martinez OM.
Decreases in circulating CD4+CD25hiFOXP3+ cells and increases in intragraft FOXP3+ cells accompany allograft rejection in pediatric liver allograft recipients.
Pediatr Transplant. 2009 Feb;13(1):70-80. Epub 2008 Mar 10. 

Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM.
Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.
Transplantation. 2008 Jan 15;85(1):145-9. 

Lambert SL, Martinez OM.
Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10.
J Immunol. 2007 Dec 15;179(12):8225-34. 

Riddle-Taylor E, Nagasaki K, Lopez J, Esquivel CO, Martinez OM, Krams SM.
Mutations to bid cleavage sites protect hepatocytes from apoptosis after ischemia/reperfusion injury.
Transplantation. 2007 Sep 27;84(6):778-85. 

Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM.
Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression.
Transplantation. 2007 Apr 27;83(8):1114-21. 

Snow AL, Martinez OM.
Epstein-Barr virus: evasive maneuvers in the development of PTLD.
Am J Transplant. 2007 Feb;7(2):271-7. Epub 2007 Jan 4. Review. 

Snow AL, Lambert SL, Natkunam Y, Esquivel CO, Krams SM, Martinez OM.
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
J Immunol. 2006 Sep 1;177(5):3283-93. 

Hsieh CL, Nagasaki K, Martinez OM, Krams SM.
NKp30 is a functional activation receptor on a subset of rat natural killer cells.
Eur J Immunol. 2006 Aug;36(8):2170-80.

Martinez OM, Rosen HR.
Basic concepts in transplant immunology.
Liver Transpl. 2005 11(4):370-81.

Obara H, Nagasaki K, Hsieh CL, Ogura Y, Esquivel CO, Martinez OM, Krams SM.
IFN-gamma,produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses.
Am J Transplant. 2005 Sep;5(9):2094-103.

Hsieh CL, Ogura Y, Obara H, Ali UA, Rodriguez GM, Nepomuceno RR, Martinez OM, Krams SM.
Identification, cloning, and characterization of a novel rat natural killer receptor, RNKP30: a molecule expressed in liver allografts.
Transplantation. 2004 Jan 15;77(1):121-8.

Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM.
Rapamycin inhibits the interleukin-10 signal transduction pathway and the growth of Epstein Barr virus B cell lymphomas.
Cancer Research. 2003 Aug 1;63(15): 4472-80.

Falco DA, Nepomuceno RR, Krams SM, Lee PP, Davis MM, Salvatierra O, Alexander SR, Esquivel CO, Cox KL, Frankel LR, Martinez OM.
Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients.
Transplantation. 2002 Aug 27;74(4):501-10.

Hsieh CL, Obara H, Ogura Y, Martinez OM, Krams SM.
NK cells and transplantation.
Transpl Immunol. 2002 May;9(2-4):111-4. Review.

Nepomuceno RR, Snow AL, Robert Beatty P, Krams SM, Martinez OM.
Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder.
Transplantation. 2002 Aug 15;74(3):396-402.

Chan KW, Hopke CD, Krams SM, Martinez OM.
CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses.
J Immunol. 2002 Aug 15;169(4):1784-91.

Millan MT, Natkunam Y, Clarke-Katzenberg R, Desai D, Prapong W, So SK, Esquivel CO, Sibley R, Ferran C, Martinez OM.
Epstein-Barr virus infection is associated with endothelial Bcl-2 expression in transplant liver allografts.
Transplantation. 2002 Feb 15;73(3):465-9.

Krams SM.
New approaches to inducing the death of alloreactive lymphocytes.
Clin Exp Immunol. 2001 Dec;126(3):371-3. Review.

Snow AL, Chen LJ, Nepomuceno RR, Krams SM, Esquivel CO, Martinez OM.
Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway.
J Immunol. 2001 Nov 1;167(9):5404-11.

Ogura Y, Martinez OM, Villanueva JC, Tait JF, Strauss HW, Higgins JP, Tanaka K, Esquivel CO, Blankenberg FG, Krams SM.
Apoptosis and allograft rejection in the absence of CD8+ T cells.
Transplantation. 2001 Jun 27;71(12):1827-34.

Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM.
Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis.
Liver. 2001 Aug;21(4):272-9.

Ogura Y, Krams SM, Martinez OM, Kopiwoda S, Higgins JP, Esquivel CO, Strauss HW, Tait JF, Blankenberg FG.
Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation.
Radiology. 2000 Mar;214(3):795-800.

Martinez OM, Krams SM.
Involvement of Fas-Fas ligand interactions in graft rejection.
Int Rev Immunol. 1999;18(5-6):527-46. Review.